Results
Cohance Lifesciences Q2 FY27 Sequential Revenue Growth 13%
Cohance Lifesciences reported Q2 FY27 revenue of INR 4,767 million, up 13% sequentially, with adjusted EBITDA improving to INR 458 million (10% margin).
The company secured two new commercial programs
